Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 7/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.68 |
| ▸ | HKDC1 | Q2TB90 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | BLM | P54132 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | G6PD | P11413 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521808 | 1.00 | FSCN1 (0.68) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL15521868 | 0.90 | FSCN1 (0.69) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL30723332 | 0.90 | FSCN1 (0.69) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL30723345 | 0.90 | FSCN1 (0.69) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL15521832 | 0.90 | FSCN1 (0.69) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL13510228 | 0.89 | FSCN1 (0.54) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL13510218 | 0.89 | FSCN1 (0.57) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL13510172 | 0.88 | KEAP1 (0.54) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL15521893 | 0.88 | FSCN1 (0.54) | FSCN1KEAP1NFE2L2HKDC1MEN1 | |
| SCHEMBL13510190 | 0.87 | KEAP1 (0.53) | FSCN1KEAP1NFE2L2HKDC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12384791-B2 | Methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11866440-B2 | Methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | FSCN1 1/4885KEAP1 1911/4885NFE2L2 2091/4885 |
| US-12384791-B2 | Methods for inhibiting fascin | FSCN1, NLN, TNNI3 | FSCN1 1/4885KEAP1 1911/4885NFE2L2 2091/4885 |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | FSCN1 1/4885KEAP1 1911/4885NFE2L2 2091/4885 |
| US-11866440-B2 | Methods for inhibiting fascin | FSCN1, NLN, TNNI3 | FSCN1 1/4885KEAP1 1911/4885NFE2L2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.